This article is more than 5 years old. Information may no longer be current.
SightGlass Vision begins trial of novel eyeglasses to control myopia
Click Here to Manage Email Alerts
SightGlass Vision announced that it is enrolling children in the U.S. and Canada for its clinical trial, CYPRESS, which will evaluate myopia control with spectacle lenses.
The CYPRESS study is evaluating the safety and efficacy of the company’s novel lenses compared to standard spectacles to reduce the rate of progression of myopia in children from 6 to 9 years old, according to a company press release.
“There are two test designs being evaluated vs. control lenses; both test designs utilize SightGlass Vision's proprietary technology, which has shown promise to reduce myopia progression in previous early stage clinical trials,” Joe Rappon, OD, MS, FAAO, SightGlass Vision chief medical officer, told Primary Care Optometry News.
The CYPRESS trial is a multicenter, double-blind, randomized controlled clinical trial that plans to enroll 255 patients across 14 clinical sites in the U.S. and Canada. The primary outcome measure is progression of myopia over 36 months.
Trial participants will be able to choose from a variety of eyeglass frames and will be asked to use one of three types of lenses instead of their normal glasses.
Interested parents can visit kidsvision.info to learn more about the study and search for a nearby clinical site.
SightGlass expects to complete trial enrollment by the end of Q1 2019 and report initial results from the CYPRESS study in 2020.